



(11) **EP 3 144 014 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 71, 72

(51) Int Cl.:
A61K 45/06 ^(2006.01) **A61K 31/437** ^(2006.01)
A61K 31/4375 ^(2006.01) **A61K 31/5377** ^(2006.01)
A61P 35/00 ^(2006.01) **A61P 35/04** ^(2006.01)

(48) Corrigendum issued on:
26.04.2017 Bulletin 2017/17

(43) Date of publication:
22.03.2017 Bulletin 2017/12

(21) Application number: **15306469.6**

(22) Date of filing: **21.09.2015**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA

(71) Applicants:
• **COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES**
75015 Paris (FR)
• **INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)**
75013 Paris (FR)

(72) Inventors:
• **GIACOSA, Sofia**
38110 LA TOUR DU PIN (FR)
• **PILLET, Catherine**
38450 VIF (FR)
• **COCHET, Claude**
38640 CLAIX (FR)
• **FILHOL-COCHET, Odile**
38640 CLAIX (FR)
• **BARETTE, Caroline**
38360 SASSENAGE (FR)
• **SOLEILHAC, Emmanuelle**
38960 SAINT ETIENNE DE CROSSEY (FR)

(74) Representative: **Gevers & Orès**
41 avenue de Friedland
75008 Paris (FR)

(54) **A SYNTHETIC LETHAL DRUG COMBINATION FOR TREATING RENAL CELL CARCINOMA**

(57) The present invention pertains to a novel treatment of renal cell carcinoma and other a solid tumors which harbor a VHL inactivation, based on the combina-

tion of a first agent inhibiting a protein kinase CK2 (CK2) and a second agent inhibiting an Ataxia Telangiectasia Mutated (ATM) kinase.

EP 3 144 014 A8